Time to End the Use of Genetic Test Results in Life Insurance Underwriting.
作者信息
Rothstein Mark A
机构信息
Mark A. Rothstein, J.D., is the Herbert F. Boehl Chair of Law and Medicine and Director of the Institute for Bioethics, Health Policy and Law at the University of Louisville School of Medicine.
出版信息
J Law Med Ethics. 2018 Sep;46(3):794-801. doi: 10.1177/1073110518804243.
Abstract
摘要
相似文献
1
Time to End the Use of Genetic Test Results in Life Insurance Underwriting.
J Law Med Ethics. 2018 Sep;46(3):794-801. doi: 10.1177/1073110518804243.
2
Bridging the gap between life insurer and consumer in the genetic testing era: the RF proposal.
Indiana Law J. 1999 Autumn;74(4):1375-95.
3
4
The political reality of underwriting issues.
Med Sect Proc. 1994:227-38.
5
Direct-to-Consumer Genetic Testing and Potential Loopholes in Protecting Consumer Privacy and Nondiscrimination.
JAMA. 2019 May 21;321(19):1869-1870. doi: 10.1001/jama.2019.3384.
6
Genetic information and life insurance: a 'real' risk?
Eur J Hum Genet. 2003 Aug;11(8):561-4. doi: 10.1038/sj.ejhg.5200998.
7
Essentially yours: the protection of human genetic information in Australia.
Genewatch. 2006 Jan-Feb;19(1):9-12.
8
Proposal: a position for the insurance industry on genetic testing.
J Insur Med. 1997;29(4):260-2.
9
Genetic discrimination: meeting the challenges of an emerging issue.
Univ N S W Law J. 2003;26(3):764-9.
10
Implications of genetic testing: discrimination in life insurance and future directions.
J Law Med. 2003 May;10(4):470-87.
引用本文的文献
1
The Legal Uncertainties of Sociogenomic Polygenic Scores.
Harv J Law Technol. 2024;38(2 Symposium):553-576.
2
The silent spread: exploring diverse metastatic pathways in high-grade serous ovarian cancer.
Front Med (Lausanne). 2025 Mar 5;12:1539024. doi: 10.3389/fmed.2025.1539024. eCollection 2025.
3
Genomics and insurance in the United Kingdom: increasing complexity and emerging challenges.
Health Econ Policy Law. 2024 Oct;19(4):446-458. doi: 10.1017/S1744133124000070. Epub 2024 May 16.
4
Cascade genetic testing for hereditary cancer syndromes: a review of barriers and breakthroughs.
Fam Cancer. 2024 Jun;23(2):111-120. doi: 10.1007/s10689-024-00373-4. Epub 2024 Mar 26.
5
Community concerns about genetic discrimination in life insurance persist in Australia: A survey of consumers offered genetic testing.
Eur J Hum Genet. 2024 Mar;32(3):286-294. doi: 10.1038/s41431-023-01373-1. Epub 2023 May 11.
6
Attitudes of Australian dermatologists on the use of genetic testing: A cross-sectional survey with a focus on melanoma.
Front Genet. 2022 Oct 24;13:919134. doi: 10.3389/fgene.2022.919134. eCollection 2022.
7
Genetic testing and insurance implications: Surveying the US general population about discrimination concerns and knowledge of the Genetic Information Nondiscrimination Act (GINA).
Risk Manag Insur Rev. 2021 Winter;24(4):341-365. doi: 10.1111/rmir.12195. Epub 2021 Nov 19.
8
Genetic information, insurance and a pluralistic approach to justice.
J Med Ethics. 2021 Apr 15;47(7):473-9. doi: 10.1136/medethics-2020-106913.
9
A survey of U. S. state insurance commissioners concerning genetic testing and life insurance: Redux at 27.
J Genet Couns. 2020 Dec;29(6):928-935. doi: 10.1002/jgc4.1197. Epub 2019 Dec 18.
10
Genetic discrimination by Australian insurance companies: a survey of consumer experiences.
Eur J Hum Genet. 2020 Jan;28(1):108-113. doi: 10.1038/s41431-019-0426-1. Epub 2019 Jul 8.
本文引用的文献
1
Insurance Risk Classification in an Era of Genomics: Is a Rational Discrimination Policy Rational?
Neb Law Rev. 2017;96(3):624-687.
2
Nanopore sequencing and assembly of a human genome with ultra-long reads.
Nat Biotechnol. 2018 Apr;36(4):338-345. doi: 10.1038/nbt.4060. Epub 2018 Jan 29.
3
'Liquid biopsy' for cancer promises early detection.
Science. 2018 Jan 19;359(6373):259. doi: 10.1126/science.359.6373.259.
4
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Lancet Oncol. 2018 Feb;19(2):169-180. doi: 10.1016/S1470-2045(17)30891-4. Epub 2018 Jan 11.
5
Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.
JAMA. 2018 Jan 9;319(2):154-164. doi: 10.1001/jama.2017.19130.
6
The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer.
Clin Genet. 2018 May;93(5):1063-1068. doi: 10.1111/cge.13191. Epub 2018 Mar 25.
7
TANTAMOUNT TO FRAUD?: EXPLORING NON-DISCLOSURE OF GENETIC INFORMATION IN LIFE INSURANCE APPLICATIONS AS GROUNDS FOR POLICY RESCISSION.
Health Matrix Clevel. 2016;26:255-307.
8
Clinical Next Generation Sequencing for Precision Medicine in Cancer.
Curr Genomics. 2015 Aug;16(4):253-63. doi: 10.2174/1389202915666150511205313.
9
Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.
Clin Cancer Res. 2016 Aug 1;22(15):3971-81. doi: 10.1158/1078-0432.CCR-15-1465. Epub 2016 Mar 15.
10
LIMITING OCCUPATIONAL MEDICAL EVALUATIONS UNDER THE AMERICANS WITH DISABILITIES ACT AND THE GENETIC INFORMATION NONDISCRIMINATION ACT.
Am J Law Med. 2015;41(4):523-67. doi: 10.1177/0098858815622190.
Zotero 插件